Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KEAP1 Gene Mutation”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Ended earlyNCT04265534
What this trial is testing

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Who this might be right for
Non-Small Cell Lung CancerNon-squamous Non-small-cell Lung CancerNon-Squamous Non-Small Cell Neoplasm of Lung+3 more
Calithera Biosciences, Inc 40
Testing effectiveness (Phase 2)Looking for participantsNCT05276726
What this trial is testing

JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Who this might be right for
Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT03872427
What this trial is testing

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmNF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor+1 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Looking for participantsNCT06341660
What this trial is testing

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease 30
Large-scale testing (Phase 3)Looking for participantsNCT06008093
What this trial is testing

Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 280
Not applicableEnded earlyNCT04698681
What this trial is testing

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Who this might be right for
Non-Small Cell Lung CancerNon-squamous Non-small-cell Lung CancerNon-Squamous Non-Small Cell Neoplasm of Lung+3 more
Calithera Biosciences, Inc 20
Early research (Phase 1)Active Not RecruitingNCT05462717
What this trial is testing

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma+1 more
Revolution Medicines, Inc. 222
Testing effectiveness (Phase 2)Study completedNCT05054725
What this trial is testing

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Who this might be right for
Non-Small Cell Lung Cancer
Revolution Medicines, Inc. 47